Eton Pharmaceuticals, Inc. (ETON): Price and Financial Metrics

Eton Pharmaceuticals, Inc. (ETON)

Today's Latest Price: $5.42 USD

0.27 (5.24%)

Updated Jun 5 4:00pm

Add ETON to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 214 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ETON Stock Summary

  • ETON's went public 1.56 years ago, making it older than merely 2.05% of listed US stocks we're tracking.
  • ETON's price/sales ratio is 193.05; that's higher than the P/S ratio of 98.34% of US stocks.
  • With a year-over-year growth in debt of 3,740.34%, Eton Pharmaceuticals Inc's debt growth rate surpasses 99.1% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Eton Pharmaceuticals Inc, a group of peers worth examining would be LPCN, EPZM, CAPR, VBIV, and CLSN.
  • ETON's SEC filings can be seen here. And to visit Eton Pharmaceuticals Inc's official web site, go to
ETON Daily Price Range
ETON 52-Week Price Range

ETON Stock Price Chart More Charts

ETON Price/Volume Stats

Current price $5.42 52-week high $9.07
Prev. close $5.15 52-week low $2.50
Day low $5.11 Volume 76,334
Day high $5.42 Avg. volume 77,929
50-day MA $4.66 Dividend yield N/A
200-day MA $5.71 Market Cap 113.37M

Eton Pharmaceuticals, Inc. (ETON) Company Bio

Eton Pharmaceuticals Inc. Eton Pharmaceuticals, Inc. is a is a specialty pharmaceutical company, which is focused on developing and commercializing pharmaceutical products. It products include EM-100, ET-103, CT-100, DS-300, DS-200, and DS-100. The Company focuses on product candidates that are liquid in formulation, including injections, oral liquids and ophthalmics. EM-100 is an ophthalmic product with a preservative-free formulation of the active ingredient ketotifen, and is indicated for the treatment of allergic conjunctivitis. ET-103 is an oral liquid formulation of levothyroxine, which is widely used in tablet and capsule form, and is indicated for the treatment of hypothyroidism. CT-100 is our patent-pending synthetic corticotropin therapeutic candidate that mimics the amino acid chain of injectable product H.P. Acthar Gel. DS-300 is a patent-pending injectable product candidate indicated to treat nutritional deficiencies. DS-200 is an injectable product candidate indicated to treat pain management.

ETON Latest News Stream

Event/TimeNews Detail
Loading, please wait...

ETON Latest Social Stream

Loading social stream, please wait...

View Full ETON Social Stream

Latest ETON News From Around the Web

Below are the latest news stories about Eton Pharmaceuticals Inc that investors may wish to consider to help them evaluate ETON as an investment opportunity.

Hedge Funds Nibbling On Eton Pharmaceuticals, Inc. (ETON)

Before we spend countless hours researching a company, we like to analyze what insiders, hedge funds and billionaire investors think of the stock first. This is a necessary first step in our investment process because our research has shown that the elite investors' consensus returns have been exceptional. In the following paragraphs, we find out […]

Yahoo | June 4, 2020

Eton Pharmaceuticals, Inc. (ETON) Reports Q1 Loss, Lags Revenue Estimates

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -108.33% and -93.89%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research | May 14, 2020

Eton Pharmaceuticals Announces First Quarter 2020 Financial Results

DEER PARK, Ill., May 14, 2020 -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug.

Yahoo | May 14, 2020

Eton Pharmaceuticals Inc (ETON) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Eton Pharmaceuticals Inc (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research | May 7, 2020

Eton Pharmaceuticals Confirms First-to-File Patent Challenge on Elcys (Cysteine Hydrochloride Injection)

Eton Pharmaceuticals, Inc (ETON), a specialty pharmaceutical company focused on developing and commercializing innovative drug products, today disclosed that it has been confirmed as the first filer of an Abbreviated New Drug Application (ANDA) against Exela Pharma Science’s Elcys (cysteine hydrochloride injection). Eton’s Paragraph IV certifications challenge the validity of U.S. Patent Nos.

Yahoo | May 7, 2020

Read More 'ETON' Stories Here

ETON Price Returns

1-mo -0.73%
3-mo 1.88%
6-mo -10.12%
1-year -33.42%
3-year N/A
5-year N/A
YTD -24.72%
2019 17.65%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9302 seconds.